UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2233-5
Program Prior Authorization/Medical Necessity
Medication/Therapeutic Class Lithobid® (brand only)
P&T Approval Date 3/2021, 3/2022, 3/2023, 11/2023, 7/2024
Effective Date 10/1/2024
1. Background:
This program requires a member to try an AB-rated generic lithium prior to receiving
coverage for brand Lithobid.
2. Coverage Criteriaa:
A. Initial Authorization
1. Lithobid (brand only) will be approved based on one of the following criteria:
a. Both of the following:
(1) History of greater than or equal to 4 week trial of generic lithium (document
date of trial)
-AND-
(2) Documented history of an inadequate response to generic lithium (document
inadequate response)
-OR-
b. History of an intolerance to generic lithium which was unable to be resolved with
attempts to minimize the adverse effects where appropriate (e.g. change timing of
dosing, divide daily dose out for more frequent but smaller doses, lowering dose)
-OR-
c. Currently established on Lithobid and stable.
Authorization will be issued for 12 months.
B. Reauthorization
1. Lithobid (brand only) will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Reauthorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Lithobid [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc; October 2022.
2. Gitlin, M. Lithium side effects and toxicity: prevalence and management strategies. Int J
Bipolar Disord. 2016;4(1):27. Epub 2016 Dec 17.
Program Prior Authorization/Medical Necessity – Lithobid (brand only)
Change Control
Date Change
3/2021 New program.
3/2022 Annual review. No changes.
3/2023 Annual review. Updated references.
11/2023 No changes.
7/2024 Removed therapeutic levels requirement for generic trial and stability
duration.
© 2024 UnitedHealthcare Services, Inc.
2